



REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights

August 1, 2016 8:01 PM EDT

ROCKVILLE, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, August 9, 2016 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2016 and recent operational highlights.

To access the live call by phone, dial (844) 287-6621 (domestic) or (530) 379-4558 (international), and enter the passcode 59014970. To access a live or recorded webcast of the call, please visit the "Investors" section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately one week following the call.

About REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing *in vivo* gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of March 31, 2016, REGENXBIO's NAV Technology Platform was being applied in the development of 28 product candidates for a variety of diseases, including five internally developed candidates and 23 partnered candidates developed by REGENXBIO's licensees.

CONTACT: [

Investors [

Elizabeth Broder, 646-378-2945

ebroder@troutgroup.com

Media [

Laura Bagby, 312-448-8098

lbagby@6degreespr.com



REGENXBIO Inc.